Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03)

被引：0
作者：
Wen, P. Y.
Puduvalli, V.
Kuhn, J.
Reid, J.
Cloughesy, T.
Yung, W. A.
Chang, S. M.
Robbins, H. I.
McGovern, R.
Ames, M.
Prados, M. D.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] UT Southwestern, San Antonio, TX USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Wisconsin, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2039
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC).
    Fakih, M. G.
    Pendyala, L.
    Toth, K.
    Creaven, P.
    Soehnlein, N.
    Litwin, A.
    Trump, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 168S - 168S
  • [22] PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Kuhn, John
    Chang, Susan
    Lamborn, Kathleen
    Robbins, Hi
    Cloughesy, Timothy
    Lieberman, Frank
    Mehra, Minesh
    Gilbert, Mark
    Cooper, Josh
    Drappatz, Jan
    Kesari, Santosh
    Norden, Andrew
    Groves, Morris
    Aldape, Kenneth
    Yung, W. K. Alfred
    Dancey, Janet
    Prados, Michael
    NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
  • [23] Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02)
    Wen, P. Y.
    Chang, S. M.
    Kuhn, J.
    Lamborn, K.
    Robins, H. I.
    Cloughesy, T.
    Gilbert, M. R.
    Yung, W. K. A.
    Mehta, M.
    DeAngelis, L. M.
    Abrey, L. E.
    Kesari, S.
    Drappatz, J.
    Lassman, A. B.
    Dancey, J.
    Prados, M. D.
    NEURO-ONCOLOGY, 2006, 8 (04) : 454 - 454
  • [24] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
    Peters, Katherine B.
    Lipp, Eric S.
    Miller, Elizabeth
    Herndon, James E., II
    McSherry, Frances
    Desjardins, Annick
    Reardon, David A.
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 349 - 356
  • [25] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
    Katherine B. Peters
    Eric S. Lipp
    Elizabeth Miller
    James E. Herndon
    Frances McSherry
    Annick Desjardins
    David A. Reardon
    Henry S. Friedman
    Journal of Neuro-Oncology, 2018, 137 : 349 - 356
  • [26] Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    Richardson, Paul G.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Reilly, Eileen
    McBride, Laura
    Chiao, Judy
    Sun, Linda
    Ricker, Justin L.
    Rizvi, Syed
    Oerth, Carol
    Atkins, Barbara
    Fearen, Ivy
    Anderson, Kenneth C.
    Siegel, David S.
    BLOOD, 2007, 110 (11) : 357A - 357A
  • [27] A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
    Kurzrock, Razelle
    Galanis, Evanthia
    Johnson, Derek Richard
    Kansra, Vikram
    Wilcoxen, Keith
    Mcclure, Ty
    Martell, Robert E.
    Agarwal, Shefall
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG)
    Desjardins, A.
    Reardon, D. A.
    Gururangan, S.
    Peters, K.
    Threatt, S.
    Friedman, A.
    Friedman, H.
    Vredenburgh, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Garcia-Manero, Guillermo
    Yang, Hui
    Bueso-Ramos, Carlos
    Ferrajoli, Alessandra
    Cortes, Jorge
    Wierda, William G.
    Faderl, Stefan
    Koller, Charles
    Morris, Gail
    Rosner, Gary
    Loboda, Andrey
    Fantin, Valeria R.
    Randolph, Sophia S.
    Hardwick, James S.
    Reilly, John F.
    Chen, Cong
    Ricker, Justin L.
    Secrist, J. Paul
    Richon, Victoria M.
    Frankel, Stanley R.
    Kantarjian, Hagop M.
    BLOOD, 2008, 111 (03) : 1060 - 1066
  • [30] A phase I trial of combination motexafin gadolinium (MGD) and temozolomide in malignant gliomas
    Shapiro, W. R.
    Ashby, L. S.
    Phan, S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 451 - 452
12345